Author

W. C. Shropshire

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:E. coli· 2 Approach:experimental assay· 2 Research Focus:host-pathogen & immune response· 2 Assay:whole-genome sequencing· 2 Research Focus:clustering· 1 Research Focus:differential expression· 1 Organism:human· 1 Assay:proteomics· 1

Frequent Co-Authors

A. Khan· 2 shared M. M. Bhatti· 2 shared S. A. Shelburne· 2 shared A. Kalia· 1 shared A. Kawai· 1 shared A. Q. Dinh· 1 shared A. R. Flores· 1 shared A. Wanger· 1 shared

Activity by Year

2019-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMicrobiology

A. Khan

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Temporal Dynamics of Genetically Heterogeneous Extended-Spectrum Cephalosporin Resistant Escherichia coli Bloodstream Infections

W. C. Shropshire, B. Strope, S. Selvaraj Anand, J. Bremer, P. McDaneld, M. M. Bhatti, A. R. Flores, A. Kalia, S. A. Shelburne

This study uses whole genome sequencing to analyze the temporal dynamics and genetic diversity of extended-spectrum cephalosporin-resistant Escherichia coli bloodstream infections in a U.S. cancer center, revealing stable STc131 prevalence and heterogeneous clonal complexes driving infection peaks.

bioRxiv · Feb 7, 2023Microbiology

High-level ceftazidime-avibactam resistance in Escherichia coli conferred by the novel plasmid-mediated beta-lactamase CMY-185 variant

W. C. Shropshire, B. T. Endres, J. Borjan, S. L. Aitken, W. C. Bachman, C. L. McElheny, A. Khan, M. M. Bhatti, P. Saharasbhojane, A. Kawai, R. K. Shields, S. A. Shelburne, Y. Doi

The paper identifies a novel CMY-185 beta-lactamase variant in E. coli that confers high-level resistance to ceftazidime-avibactam through specific amino acid substitutions.

bioRxiv · Feb 3, 2023Microbiology

Extremely Drug-Resistant Pseudomonas aeruginosa ST309 Harboring Tandem GES Enzymes: A Newly Emerging Threat in the United States

A. Khan, T. T. Tran, R. Rios, B. Hanson, W. C. Shropshire, Z. Sun, L. Diaz, A. Q. Dinh, A. Wanger, L. Ostrosky-Zeichner, T. Palzkill, C. A. Arias, W. R. Miller

The paper identifies two U.S. clinical isolates of Pseudomonas aeruginosa ST309 resistant to carbapenems and beta-lactam/beta-lactamase inhibitor combinations, harboring tandem GES 19 and 26 enzymes, and reports successful treatment with ceftazidime/avibactam plus aztreonam.

bioRxiv · Jan 30, 2019Microbiology